August 2026 Options Now Available For Colgate-Palmolive (CL)

Colgate-Palmolive (CL) stock is trading at $78.79; a $75.00 put is bidding $1.50 (effective purchase basis $73.50) with a 66% probability of expiring worthless and a 2.00% yield on cash (2.97% annualized). On the call side, the $80.00 strike bids $3.50; selling a covered call from $78.79 would produce a 5.98% total return if called at the August 2026 expiration, with a 48% chance of expiring worthless and a 4.44% yield boost (6.59% annualized). Implied volatility for these contracts is ~22% versus a 12‑month trailing volatility of 21%; Stock Options Channel will track contract odds and histories on its site.

Analysis

Market structure: Option sellers and yield-seeking retail/institutional buy-write desks are the immediate beneficiaries; dealers capture bid-ask spread and gamma exposure. Colgate (CL) shareholders face modest upside-capping if covered-call activity scales, but balance-sheet/credit markets are largely unaffected given staples’ low leverage. The 22% implied vol ≈ 21% realized vol implies markets see no large near-term shock; supply of put/call premium supply is meeting demand for income, compressing option-implied returns to mid-single digits annualized.

Risk assessment: Tail risks include rapid EM FX depreciation (>10%) or a commodity shock (palm oil, sodium stearate) that hits margins—these would materially widen IV >30% and push CL equity -10%+. Short-term (days-weeks) the dominant risks are IV spikes around earnings or geopolitics; medium-term (months) is margin compression from input inflation; long-term (years) is secular share loss to private-label competition. Hidden dependencies: call/put selling concentrations can create forced buying if assignments cluster, amplifying short-term moves.

Trade implications: For income-focused portfolios, cash-secured $75 puts Aug 2026 (collect $1.50 → $73.50 basis) is an attractive entry with a 66% OTM win probability and 2.97% annualized yield; covered-call buy-writes at $80 collect $3.50 for ~6.6% annualized upside-to-call. Avoid naked short vol; prefer structured, size-limited positions (1–3% notional) with pre-defined buyback triggers (price or IV thresholds).

Contrarian angles: Consensus underestimates the value of active option-selling scale — if many retail desks employ identical yield tactics, upside supply can persist and cap rallies, making buy-write strategies structurally attractive but limiting multi-quarter capital appreciation. Historical parallels: staples retained relative outperformance in past 10–20% equity drawdowns; unintended consequence—overcrowded put selling could force large assignments and create transient long squeezes in CL shares.

Key Decisions for Investors

• Establish a cash-secured short CL Aug 2026 $75 put position sized to 1–3% portfolio notional (sell-to-open at ~$1.50). Rationale: effective entry $73.50, 66% OTM probability, 2.97% annualized yield. Exit/buyback if CL < $70, IV >30%, or within 30 days if imminent negative catalyst.
• Implement a buy-write: purchase CL up to 2% portfolio weight and sell Aug 2026 $80 covered calls for ~$3.50 (net capped return ≈5.98; annualized YieldBoost ≈6.59%). Buy back calls if CL > $83 or call delta >0.60 (to preserve >5% further upside) or if realized volatility >> implied.
• Do not sell naked volatility; if initiating >3% exposure purchase 6–9 month protective puts (e.g., $70–$75 strike) if premium ≤2.5% absolute or if IV jumps above 30%. Monitor quarterly earnings dates and emerging-market FX moves >5% within 30 days as immediate catalyst triggers to adjust positions.